Global Psoriasis Drug Market, US$million and Y-o-Y growth
Source: Transparency Market Research, 2019
Psoriasis and its Burden
- Psoriasis represents a major health problem globally. It is a chronic, recurrent, painful, disfiguring and disabling disease for which there is no cure. It may cover large parts of the body with patches which may heal and then come back repeatedly throughout a person’s life, causing negative effects on the quality, social, mental and productive life of sufferers.
- Individuals with psoriasis are at higher risk of developing a number of other serious, systemic and impactful clinical conditions, including cardiovascular diseases, diabetes, malignancies, mental disorders, COPD, hepatic disease, multiple sclerosis, renal and inflammatory bowel disease.
- Psoriasis represents a global health problem, with a prevalence ranging between 1% and 3% in most countries. More than 100 million people globally suffer from psoriasis, with 9 million of them in the USA and 14 million in Europe. Due to demographic trends new cases of psoriasis are emerging annually at a fast rate.
- The burden of psoriasis is comparable with that of other serious chronic illnesses, such as cancer and cardiovascular diseases. In the USA the annual direct care costs of psoriasis were estimated at $63.2 billion, medical comorbidities were estimated to contribute $36.4 billion, losses of productivity $35.4 billion, so that overall it accounts for approximately $112 billion
Global Topical Psoriasis Drug Market, US$ million and Y-o-Y growth
Source: Transparency Market Research, 2019
Unmet Needs and Market Opportunity
- There is no cure for psoriasis and care aims to treat skin manifestations, mainly by means of topical drugs for mild and moderate cases, accounting for 70% to 80% of all, and systemic drugs for the remaining severe cases
- Currently approved mainstream topical treatments are suboptimal in terms of safety and efficacy, causing low satisfaction and adherence rates. Safety issues and high cost also represent a concern for long term systemic drug use. Thus, there significant un-treatment and under-treatment and yet serious unmet needs to be covered.
- The global psoriasis drug market will exhibit a significant growth in the near future and is expected to double in size to 2027, when it is forecasted reach $35.7 billion. The topical segment, is also expected to exhibit rapid growth and is forecast to also double in size between today and 2027, when it is expected to reach $3.5 billion globally.
